Inactivated equine rhinopneumonitis virus vaccine and use thereof
AssigneeUniversity of Kentucky Research Foundation
InventorJohn T. Bryans
Life of this patent
Estimating the term…
Abstract
An inactivated viral vaccine for protecting horses against disease caused by equine rhinopneumonitis virus is prepared by propagating an equine rhinopneumonitis virus in a susceptible, cloned, diploid equine cell line, harvesting the resulting virus in a serum-free medium, inactivating the virus and neutralizing the inactivating agent, concentrating the virus, and adding an immunological adjuvant thereto. A vaccination program to protect horses against the equine rhinopneumonitis virus is also disclosed.
Claims9
A vaccination method against disease caused by equine rhinopneumonitis virus in horses which comprises (a) vaccinating young female horses at any age past the time they reach their sixth month of age and revaccinating them at appropriate intervals until the females reach breeding age and become pregnant and (b) vaccinating the pregnant mares during their pregnancy and during subsequent pregnancies with an adjuvanted, inactivated vaccine prepared by:
- propagating a virulent, immunogenically typical equine rhinopneumonitis virus in a susceptible, cloned, diploid equine cell line that contains no equine blood cell antigens, and causing the virus to be released into a serum-free medium;
- harvesting virus from the cell culture, inactivating the virus, neutralizing the inactivating agent, concentrating the virus and adding an oil based immunological adjuvant thereto.
The method of preparing a vaccine for parenteral vaccination of horses against disease caused by equine rhinopneumonitis virus which comprises:
- propagating a virulent, immunogenically typical equine rhinopneumonitis virus in a susceptible equine, cloned, physiologically homogeneous, diploid cell line and multiplying the virus to obtain high yields of infectious virions;
- harvesting the virus in a serum free medium;
- completely inactivating the virions, neutralizing the inactivating agent, concentrating the virions by a method that maintains structural integrity and increases antigenic potency;
- and
- mixing the concentrated, inactivated virions with an oil based immunological adjuvant,
- said harvested and adjuvant mixed material meeting the following criteria for safety and potency;
- (a) the virus is shown to be inactivated and non-infective by its lack of ability to infect susceptible cell cultures, and
- (b) the vaccine is shown to be immunogenically potent by protection of hamsters against one million hamster median lethal doses of hamster virulent rhinopneumonitis virus.
Dependencies are inferred from the claim text.